Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
暂无分享,去创建一个
Y. Kato | S. Murata | K. Hosoya | T. Okagawa | N. Maekawa | Yasuhiko Suzuki | T. Deguchi | Keiichi Yamamoto | Yumiko Kagawa | Hiroto Takeuchi | Satoshi Yamamoto | Ryo Owaki | Kazuhiko Ohashi | Ryohei Kinoshita | Madoka Yokokawa | Satoshi Takagi | Hiroshi Ohta | Satoru Konnai | Sangho Kim | Yurika Tachibana
[1] M. Okumura,et al. Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines. , 2023, Veterinary and comparative oncology.
[2] M. Santoni,et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis , 2023, Cancer Immunology, Immunotherapy.
[3] T. Hupp,et al. Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma , 2022, Cancers.
[4] Marcel P. Trefny,et al. Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment , 2022, Science Translational Medicine.
[5] M. Nakaichi,et al. Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report. , 2022, Veterinary and comparative oncology.
[6] C. Lacchetti,et al. Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. , 2022, JCO oncology practice.
[7] G. Brandi,et al. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects , 2021, Expert opinion on investigational drugs.
[8] C. Yee,et al. Hematologic complications of immune checkpoint inhibitors , 2021, Blood.
[9] D. Thamm,et al. Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] Takashi Kimura,et al. Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages , 2021, Scientific Reports.
[11] K. Ohashi,et al. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma , 2021, npj Precision Oncology.
[12] W. Hennink,et al. Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other? , 2021, Theranostics.
[13] Kongming Wu,et al. Regulation of PD-L1 expression in the tumor microenvironment , 2021, Journal of Hematology & Oncology.
[14] Jun Wang,et al. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review , 2020, Frontiers in Oncology.
[15] E. Engleman,et al. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.
[16] M. Nakaichi,et al. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs , 2020, Scientific Reports.
[17] G. Johnson,et al. Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma , 2020, Journal of veterinary internal medicine.
[18] K. Ohashi,et al. Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers , 2020, Frontiers in Veterinary Science.
[19] T. Nakano,et al. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment , 2020, International Journal of Clinical Oncology.
[20] G. Coukos,et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.
[21] T. Yonezawa,et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer , 2019, Cancer Immunology Research.
[22] S. Sudarsanam,et al. Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases , 2019, Modern Pathology.
[23] T. Chan,et al. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.
[24] D. Knapp,et al. Canine (Pet Dog) Tumor Microsurgery and Intratumoral Concentration and Safety of Metronomic Chlorambucil for Spontaneous Glioma: A Phase I Clinical Trial. , 2018, World neurosurgery.
[25] T. Schumacher,et al. Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.
[26] H. Weng,et al. Retrospective comparison of three doses of metronomic chlorambucil for tolerability and efficacy in dogs with spontaneous cancer† , 2017, Veterinary and comparative oncology.
[27] K. Ohashi,et al. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma , 2017, Scientific Reports.
[28] A. Caldwell,et al. Immune regulation of canine tumour and macrophage PD‐L1 expression , 2017, Veterinary and comparative oncology.
[29] Tasuku Honjo,et al. Cancer immunotherapies targeting the PD-1 signaling pathway , 2017, Journal of Biomedical Science.
[30] K. Ohashi,et al. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma , 2016, PloS one.
[31] Kumi Y. Inoue,et al. Programmed Cell Death Ligand 1 Expression in Canine Cancer. , 2016, In vivo.
[32] D. Thamm,et al. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2015, Veterinary and comparative oncology.
[33] K. Sugiura,et al. A current life table and causes of death for insured dogs in Japan. , 2015, Preventive veterinary medicine.
[34] T. Fan,et al. The Immunotherapy of Canine Osteosarcoma: A Historical and Systematic Review , 2015, Journal of veterinary internal medicine.
[35] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[36] K. Ohashi,et al. Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade , 2014, PloS one.
[37] D. Knapp,et al. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. , 2013, Journal of the American Veterinary Medical Association.
[38] Lieping Chen,et al. Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.
[39] M. Sznol,et al. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer , 2013, Clinical Cancer Research.
[40] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[41] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[42] V. Adams,et al. Methods and mortality results of a health survey of purebred dogs in the UK. , 2010, The Journal of small animal practice.
[43] N. Toft,et al. Data from the Danish Veterinary Cancer Registry on the occurrence and distribution of neoplasms in dogs in Denmark , 2010, Veterinary Record.
[44] John Launer. Supervision , 2008, Postgraduate Medical Journal.
[45] P. Bergman. Canine oral melanoma. , 2007, Clinical techniques in small animal practice.
[46] M. Salah,et al. Methodology , 2003 .
[47] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[48] J. Wood,et al. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. , 2002, The Journal of small animal practice.
[49] R. Bronson. Variation in age at death of dogs of different sexes and breeds. , 1982, American journal of veterinary research.
[50] D. Y. Kim,et al. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors , 2017, Veterinary and comparative oncology.
[51] Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. , 2016, Veterinary and comparative oncology.
[52] R. Neal. PROJECT ADMINISTRATION , 2009 .
[53] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.